ImmuCell (ImmuCell) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of ImmuCell is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of ImmuCell's Risk Assessment

For the Biotechnology subindustry, ImmuCell's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuCell's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Risk Assessment distribution charts can be found below:

* The bar in red indicates where ImmuCell's Risk Assessment falls into.

ImmuCell (NAS:ICCC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

ImmuCell Risk Assessment Related Terms

Thank you for viewing the detailed overview of ImmuCell's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuCell (ImmuCell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

IUL:Germany

Address

56 Evergreen Drive, Portland, ME, USA, 04103

Website

https://www.immucell.com

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.

Executives

Bryan K. Gathagan	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen	director	C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin	other: See Explanation of Responses	C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin	other: See Explanation of Responses	310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb	director, officer: Vice President and CSO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams	officer: Vice Pres. of Mfg Operations	C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild	director, 10 percent owner	C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham	director, officer: President and CEO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde	other: Director of Sales and Marketin	56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce	director	56 EVERGREEN DRIVE, PORTLAND ME 04103